DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE

David S Alberts, B. G M Durie, S. E. Salmon

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

A combination of doxorubicin ('Adriamycin') and B.C.N.U. (1,3 di[2-chloroethyl]-1-nitrosourea) (30 mg/m2 of each drug intravenously every 3-4 weeks) was used to treat thirteen multiple-myeloma patients who did not respond or were in relapse after remission produced by alkylating-agent/ prednisone therapy. All cases were staged according to total-body myeloma-cell number and followed quantitatively for response to therapy. Seven of the thirteen patients responded (54%). Two had complete clinical remissions and a greater than 75% reduction in tumour-cell mass lasting 12 and 16 months. Five others had partial remissions with lesser degrees of tumour-mass reduction and bone pain and improved hæmoglobin and serum-albumin concentrations. Toxicity was limited to occasional myelo-suppression, mild alopecia, and nausea. The results indicate the usefulness of doxorubicin/B.C.N.U. for myeloma patients who have relapsed during previously effective alkylating-agent therapy.

Original languageEnglish (US)
Pages (from-to)926-928
Number of pages3
JournalThe Lancet
Volume307
Issue number7966
DOIs
StatePublished - May 1 1976
Externally publishedYes

Fingerprint

Carmustine
Multiple Myeloma
Doxorubicin
Alkylating Agents
Recurrence
Drug Therapy
Alopecia
Prednisone
Serum Albumin
Nausea
Neoplasms
Therapeutics
Cell Count
Bone and Bones
Pain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE. / Alberts, David S; Durie, B. G M; Salmon, S. E.

In: The Lancet, Vol. 307, No. 7966, 01.05.1976, p. 926-928.

Research output: Contribution to journalArticle

Alberts, David S ; Durie, B. G M ; Salmon, S. E. / DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE. In: The Lancet. 1976 ; Vol. 307, No. 7966. pp. 926-928.
@article{8c6fc001c5514e1a8e403f5572630cd5,
title = "DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE",
abstract = "A combination of doxorubicin ('Adriamycin') and B.C.N.U. (1,3 di[2-chloroethyl]-1-nitrosourea) (30 mg/m2 of each drug intravenously every 3-4 weeks) was used to treat thirteen multiple-myeloma patients who did not respond or were in relapse after remission produced by alkylating-agent/ prednisone therapy. All cases were staged according to total-body myeloma-cell number and followed quantitatively for response to therapy. Seven of the thirteen patients responded (54{\%}). Two had complete clinical remissions and a greater than 75{\%} reduction in tumour-cell mass lasting 12 and 16 months. Five others had partial remissions with lesser degrees of tumour-mass reduction and bone pain and improved h{\ae}moglobin and serum-albumin concentrations. Toxicity was limited to occasional myelo-suppression, mild alopecia, and nausea. The results indicate the usefulness of doxorubicin/B.C.N.U. for myeloma patients who have relapsed during previously effective alkylating-agent therapy.",
author = "Alberts, {David S} and Durie, {B. G M} and Salmon, {S. E.}",
year = "1976",
month = "5",
day = "1",
doi = "10.1016/S0140-6736(76)92710-0",
language = "English (US)",
volume = "307",
pages = "926--928",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7966",

}

TY - JOUR

T1 - DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE

AU - Alberts, David S

AU - Durie, B. G M

AU - Salmon, S. E.

PY - 1976/5/1

Y1 - 1976/5/1

N2 - A combination of doxorubicin ('Adriamycin') and B.C.N.U. (1,3 di[2-chloroethyl]-1-nitrosourea) (30 mg/m2 of each drug intravenously every 3-4 weeks) was used to treat thirteen multiple-myeloma patients who did not respond or were in relapse after remission produced by alkylating-agent/ prednisone therapy. All cases were staged according to total-body myeloma-cell number and followed quantitatively for response to therapy. Seven of the thirteen patients responded (54%). Two had complete clinical remissions and a greater than 75% reduction in tumour-cell mass lasting 12 and 16 months. Five others had partial remissions with lesser degrees of tumour-mass reduction and bone pain and improved hæmoglobin and serum-albumin concentrations. Toxicity was limited to occasional myelo-suppression, mild alopecia, and nausea. The results indicate the usefulness of doxorubicin/B.C.N.U. for myeloma patients who have relapsed during previously effective alkylating-agent therapy.

AB - A combination of doxorubicin ('Adriamycin') and B.C.N.U. (1,3 di[2-chloroethyl]-1-nitrosourea) (30 mg/m2 of each drug intravenously every 3-4 weeks) was used to treat thirteen multiple-myeloma patients who did not respond or were in relapse after remission produced by alkylating-agent/ prednisone therapy. All cases were staged according to total-body myeloma-cell number and followed quantitatively for response to therapy. Seven of the thirteen patients responded (54%). Two had complete clinical remissions and a greater than 75% reduction in tumour-cell mass lasting 12 and 16 months. Five others had partial remissions with lesser degrees of tumour-mass reduction and bone pain and improved hæmoglobin and serum-albumin concentrations. Toxicity was limited to occasional myelo-suppression, mild alopecia, and nausea. The results indicate the usefulness of doxorubicin/B.C.N.U. for myeloma patients who have relapsed during previously effective alkylating-agent therapy.

UR - http://www.scopus.com/inward/record.url?scp=0017273268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017273268&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(76)92710-0

DO - 10.1016/S0140-6736(76)92710-0

M3 - Article

C2 - 57335

AN - SCOPUS:0017273268

VL - 307

SP - 926

EP - 928

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7966

ER -